The Judicial Panel for Multidistrict Litigation has authorized the transfer of dozens of lawsuits over the diabetes drug Invokana to a New Jersey federal court, centralizing the litigation.

In an order issued Dec. 8, the panel approved the request to centralize the cases in the U.S. District Court for the District of New Jersey by plaintiffs in 29 cases already filed there. In its entirety, the combined litigation consists of 55 cases against drugmaker Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]